Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease

Posted as supplied by author.

w1. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19: 936-43.

w2. Bourbeau J, Ernst P, Cockcoft D, Suissa S. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003; 22: 286-9.

w3. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-9.

w4. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-60.

w5. Cazzola M, Marco FD, Santus P, Boveri B, Verga M, Matera MG et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17: 35-9.

w6. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-8.

w7. Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS et al. The addition of salmeterol 50 μg bid to anticholinergic treatment in patients with COPD: A randomized, placebo controlled trial. Can Respir J 2002; 9: 178-85.

w8. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Jr. et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.

w9. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97: 1014-20.

w10. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.

w11. Liesker JJ, Van De Velde V, Meysman M, Vincken W, Wollmer P, Hansson L et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 2002; 96: 559-66.

w12. Nannini L, Lasserson T, Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; 4: CD003794.

w13. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos.Int 2003; 14: 179-90.

w14. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819-25.

w15. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23: 291-395.

w16. Tashkin D,.Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-9.

w17. Wadbo M, Löfdahl CG, Larsson K, Skoogh BE, Tornling G, Arweström E et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138-46.

w18. Wilson JD, Serby CW, Menjoge SS, Witek TJJ. The efficacy and safety of combination bronchodilator therapy. Eur Respir Rev 1996; 6: 286-9.